NewcelX NCEL 深 沪
等待开盘 10-12 09:30:00 美东时间
3.045
-0.065
-2.09%
华盛通- 最 高3.0819
- 今 开3.02
- 成交量 1586股
- 最 低 3.02
- 昨 收 3.11
- 总市值 1758.83万
- 52周最高 17.25
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 1.8299
- 委 比 -68.94%
- 总股本 577.61万
- 历史最高 2940.00
- 量 比 0.34
- 振 幅 1.99%
- 历史最低 1.8299
- 每 手 1
- 风险率 3.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
NewcelX Ltd. (Nasdaq: NCEL), a regenerative medicine company, announced its senior management will attend the Breakthrough T1D Clinical & Research Congress in Philadelphia, October 9–11, 2026. The company will discuss its lead program, NCEL-101, and preparations for its planned Phase 1/2a clinical trial in Type 1 Diabetes (T1D). Following a successful FDA Pre-IND meeting in July 2026, NewcelX has a clear path forward for IND-enabling activities, ...
09-28 12:00
NewcelX GAAP EPS of -$0.96
NewcelX press release (NCEL): 1H GAAP EPS of -$0.96. As of June 30, 2026, the company’s total equity was positive at $6,041, including cash and cash equivalents of $710. More on NLS Pharmaceutics Hist...
09-19 04:26
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
Zurich-based NewcelX Ltd. announced a private placement of 347,134 common shares at a 20% premium to its July 30 closing price, with warrants exercisable at 132% of that price. The offering, including participation from existing shareholders, is expected to close on Aug. 14. Proceeds will support the advancement of NCEL-101, the company's lead type 1 diabetes program, following a successful FDA Pre-IND meeting. CEO Ronen Twito highlighted investo...
07-31 13:00
NewcelX Issued Patent From Brazilian Patent And Trademark Office For Its Nnovative Cell Selection And Enrichment Technology
NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced that the Brazilian Patent and Trademark Office has issued Patent Number BR 112018010946-0 covering its innovative cell selection and enrichment technology. T...
07-15 21:01
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
NewcelX Ltd. has appointed Camillo Ricordi, M.D., F.N.A.I., a leading authority in diabetes research and cellular transplantation, to its Scientific Advisory Board. Dr. Ricordi's expertise will support the advancement of NewcelX's Type 1 Diabetes program and strategic collaboration with Eledon Pharmaceuticals. This appointment follows NewcelX's successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear path toward clinical trials. Dr. ...
07-08 13:15
EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submission
NewcelX submitted an FDA Pre-IND package for NCEL-101 to advance its type 1 diabetes treatment into human trials.
05-27 19:31
NewcelX FY EPS $(2.16) Up From $(2.43) YoY
NewcelX (NASDAQ:NCEL) reported quarterly losses of $(2.16) per share. This is a 11.11 percent increase over losses of $(2.43) per share from the same period last year.
04-30 20:56
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.
04-30 20:01
EXCLUSIVE: NewcelX Expects Expanded Strategic Development Collaborations For Diabetes Drug In 2026
Outlook for 2026The Company expects 2026 to be a year of accelerated execution, including: Advancing NCEL-101 toward key IND-enabling milestones Expanding strategic development collaborations Pursuing additional
04-30 20:00
